CheckMate 143
CheckMate 143 was the first large randomised test of an immune checkpoint drug in glioblastoma. When the tumour came back, nivolumab kept patients alive no longer than bevacizumab.
Overview
CheckMate 143, trial NCT02017717 sponsored by BMS, randomised 369 patients with glioblastoma at first recurrence after radiotherapy and temozolomide, open-label, to nivolumab 3 mg/kg or bevacizumab 10 mg/kg every two weeks. Median overall survival, the primary endpoint, was 9.8 versus 10.0 months (HR 1.04, 95% CI 0.83-1.30), 12-month survival was 42% in both arms, and the objective response rate was higher with bevacizumab (23.1% versus 7.8%). Published by Reardon and colleagues in JAMA Oncology in 2020. It is one of three negative phase 3 trials of nivolumab in glioblastoma, with CheckMate 498 and CheckMate 548 in newly diagnosed disease.
- Median 9.8 vs 10 months with Nivolumab compared with Bevacizumab; about 0.2 months shorter for half the group.
- A median is a midpoint: half the people did better than this and half did worse, so it is not a prediction for any one person.
- Put another way, the treated group had about 4 percent higher chance of the event at any given time (hazard ratio 1.04, likely range 0.83 to 1.3).
- The likely range for the hazard ratio crosses 1, so the difference could be due to chance.
- Overall survival counts deaths from any cause, so it is the most direct measure of whether a treatment helps people live longer.
- These results apply to the people the trial enrolled: Glioblastoma at first recurrence after radiotherapy and temozolomide: nivolumab vs bevacizumab. People in a different situation may not see the same effect.
- Not significant.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
369 participants enrolled.
Not significant
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Overall survival, first recurrence of glioblastomaprimary | Nivolumab | 184 | 9.8 months | 1.04 (0.83 to 1.3) | 0.76 | link |
| Bevacizumab | 185 | 10 months |
Similar pages
not linked directly; found by shared links- TrialCheckMate 498
Shares Neoadjuvant immunotherapy with surgical window for glioblastoma, Blood-brain barrier (BBB), Hot vs cold tumours, Nivolumab.
- TrialCheckMate 548
Shares Neoadjuvant immunotherapy with surgical window for glioblastoma, Blood-brain barrier (BBB), Hot vs cold tumours, Nivolumab.
- IdeaMaking microsatellite-stable colorectal cancer immunotherapy-responsive
Shares Hot vs cold tumours, PD-1, Immune checkpoint inhibitors.
- Key paperChen and Mellman 2013: the cancer-immunity cycle
Shares Hot vs cold tumours, PD-1, Immune checkpoint inhibitors.
- IdeaReprogramme suppressive macrophages instead of trying to delete them
Shares Hot vs cold tumours, Glioma & glioblastoma, Immune checkpoint inhibitors.
- IdeaDeliver drugs and cells to the brain through the nose
- PersonPawel Kalinski
- TechnologyCAR-T for glioma (IL13Rα2, GD2, EGFRvIII, multi-target)
Shares Neoadjuvant immunotherapy with surgical window for glioblastoma, Blood-brain barrier (BBB), Glioma & glioblastoma.